Patents by Inventor Francis J Carr

Francis J Carr has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20140072568
    Abstract: The present invention provides an antibody or antigen-binding fragment thereof that binds ?V?3 integrin, as well as methods of use in the treatment of diseases and disorders.
    Type: Application
    Filed: August 30, 2013
    Publication date: March 13, 2014
    Applicant: The University of North Carolina at Chapel Hill
    Inventors: David Clemmons, Laura Maile, Michael Naso, Francis J. Carr, Timothy D. Jones, Simon William Keen
  • Publication number: 20130291136
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Application
    Filed: March 13, 2013
    Publication date: October 31, 2013
    Inventors: Gordon J. FREEMAN, Rafi AHMED, Timothy D. JONES, Francis J. CARR, James P. GREGSON
  • Patent number: 8552154
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Grant
    Filed: September 25, 2009
    Date of Patent: October 8, 2013
    Assignees: Emory University, Dana-Farber Cancer Institute, Inc.
    Inventors: Gordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson
  • Publication number: 20130224205
    Abstract: The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct of the invention is provided. Further aspects of the invention are vectors and host cells comprising said nucleic acid sequence, a process for the production of the construct of the invention and composition comprising said construct. The invention also provides the use of said constructs for the preparation of pharmaceutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.
    Type: Application
    Filed: December 12, 2011
    Publication date: August 29, 2013
    Inventors: Robert HOFMEISTER, Birgit Kohleisen, Ulla Lenkkeri-Schütz, Christian Itin, Patrick Bäuerle, Francis J. Carr, Anita A. Hamilton, Stephen Williams
  • Patent number: 8076459
    Abstract: The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an IG-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct is provided. Further aspects of the invention are vectors and host cells comprising the nucleic acid sequences, a process for the production of the construct and composition comprising the construct. The invention also provides the use of the constructs for the preparation of pharmaceutical compositions for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.
    Type: Grant
    Filed: October 15, 2004
    Date of Patent: December 13, 2011
    Assignee: Micromet AG
    Inventors: Robert Hofmeister, Birgit Kohleisen, Ulla Lenkkeri-Schütz, Christian Itin, Patrick Bäuerle, Francis J. Carr, Anita A. Hamilton, Stephen Williams
  • Publication number: 20110271358
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Application
    Filed: September 25, 2009
    Publication date: November 3, 2011
    Applicant: Dana-Farber Cancer Institute, Inc.
    Inventors: Gordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson
  • Patent number: 7939295
    Abstract: This invention relates to the fields of immunology and protein therapeutics. The therapeutic proteins are polypeptides to be administered especially to humans. The polypeptides are modified whereby the modification results in a reduced propensity for the polypeptide to elicit an immune response upon administration to the human subject. The invention therefor provides methods for the development of therapeutic polypeptides that are less immunogenic than any non-modified counterpart when used in vivo. The modifications used according to this invention relate, for example, to the introduction of protease cleavage sites, attachment of different molecules or insertion of non-natural amino acids.
    Type: Grant
    Filed: July 12, 2002
    Date of Patent: May 10, 2011
    Assignee: Merck Patent GmbH
    Inventors: Francis J. Carr, Graham Carter, Koen Hellendoorn
  • Publication number: 20110086422
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Application
    Filed: December 20, 2010
    Publication date: April 14, 2011
    Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
  • Patent number: 7910104
    Abstract: The present invention provides for modified forms of anti-CD52 antibodies with reduced numbers of potential T-cell epitopes that are expected to display decreased immunogenicity.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: March 22, 2011
    Assignee: Merck Patent GmbH
    Inventors: Francis J. Carr, Anita A. Hamilton
  • Patent number: 7888484
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: February 15, 2011
    Assignee: Medarex, Inc.
    Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
  • Publication number: 20100286375
    Abstract: The present invention relates generally to carrier molecules derived from one animal or avian species or strains and which are substantially non-immunogenic when exposed to an immune system from a species or strain of another animal or avian creature. More particularly, the present invention provides deimmunized immunointeractive molecules and even more particular deimmunized antibodies for use in diagnostic and therapeutic applications.
    Type: Application
    Filed: January 15, 2010
    Publication date: November 11, 2010
    Inventors: Francis J. Carr, Anita A. Hamilton
  • Publication number: 20100254964
    Abstract: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
    Type: Application
    Filed: May 21, 2010
    Publication date: October 7, 2010
    Inventors: Matthew Baker, Francis J. Carr, Koen Hellendoorn, Jeannick Cizeau, Glen Christopher MacDonald, Joycelyn Entwistle, Denis Georges Bosc, Nicholas Ronald Glover
  • Patent number: 7754853
    Abstract: This invention pertains to a TNF alpha-binding polypeptide composition comprising at least one of a modified heavy chain variable region polypeptide or a modified light chain variable region polypeptide that is capable of specifically binding to human TNF alpha. The modified heavy and light chain variable region polypeptides of the TNF alpha binding polypeptide are modified by at least one amino acid residue substitution, deletion or addition and are homologous to the heavy and light chain variable regions, respectively, of a non-human monoclonal antibody that specifically binds human TNF alpha. The polypeptide compositions of the invention comprising modified heavy and light chain variable region polypeptides are less immunogenic in a human than are the homologous heavy and light chain variable region polypeptides from a non-human animal.
    Type: Grant
    Filed: December 7, 2004
    Date of Patent: July 13, 2010
    Assignee: Merck Patent GmbH
    Inventors: Koen Hellendoorn, Matthew Baker, Francis J. Carr
  • Patent number: 7750136
    Abstract: The invention provides modified forms of bouganin protein having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. The invention also provides T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. The invention also provides cytotoxins having the having a ligand that binds to a cancer cells attached to the modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins of the invention and pharmaceutical compositions for treating human cancer.
    Type: Grant
    Filed: January 9, 2008
    Date of Patent: July 6, 2010
    Assignee: Merck Patent GmbH
    Inventors: Matthew Baker, Francis J. Carr, Koen Hellendoorn, Jeannick Cizeau, Glen Christopher MacDonald, Joycelyn Entwistle, Denis Georges Bosc, Nicholas Ronald Glover
  • Publication number: 20100104569
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Application
    Filed: September 29, 2009
    Publication date: April 29, 2010
    Applicant: MEDAREX, INC.
    Inventors: Josephine M. Cardarelli, Tseng-hui Timothy Chen, David King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
  • Patent number: 7619070
    Abstract: Humanized monoclonal antibodies which bind to IFNAR-1, and related antibody-based compositions and molecules, are disclosed. Also disclosed are pharmaceutical compositions comprising the humanized antibodies and therapeutic and diagnostic methods for using the humanized antibodies.
    Type: Grant
    Filed: April 23, 2004
    Date of Patent: November 17, 2009
    Assignee: Medarex, Inc.
    Inventors: Josephine M. Cardarelli, Tseng-Hui Timothy Chen, David J. King, Christopher R. Bebbington, Sarah Lee Pogue, Francis J. Carr, Stephen Williams
  • Patent number: 7615217
    Abstract: The invention relates to artificial modified proteins, preferably fusion proteins, having a reduced immunogenicity compared to the parent non-modified molecule when exposed to a species in vivo. The invention relates, above all, to novel immunoglobulin fusion proteins which essentially consist of an immunoglobulin molecule or a fragment thereof covalently fused via its C-terminus to the N-terminus of a biologically active non-immunoglobulin molecule, preferably a polypeptide or protein or a biologically active fragment thereof. In a specific embodiment, the invention relates to fusion proteins consisting of an Fc portion of an antibody which is fused as mentioned to the non-immunological target molecule which elicits biological or pharmacological efficacy. The molecules of the invention have amino acid sequences which are altered in one or more amino acid residue positions but have in principal the same biological activity as compared with the non-altered molecules.
    Type: Grant
    Filed: March 12, 2007
    Date of Patent: November 10, 2009
    Assignee: Merck Patent GmbH
    Inventors: Stephen Gillies, Francis J. Carr, Jones Tim, Graham Carter, Anita Hamilton, Stephen Williams, Marian Hanlon, John Watkins, Matthew Baker, Jeffrey C. Way
  • Patent number: 7615615
    Abstract: The present invention relates a modified human interferon beta (INF?) which is less immunogenic than human INF? (SEQ ID NO: 1) when administered in vivo to a human. The modified human INF? comprises an amino acid residue sequence that differs from SEQ ID NO: 1 by an amino acid residue substitution selected from the group consisting of L57A, L57C, L57D L57E, L57G, L57H, L57K, L57N, L57P, L57Q, L57R, L57S, and L57T and an additional substitution selected from the group consisting of the H140A, H140C, H140G, and H140P.
    Type: Grant
    Filed: March 17, 2008
    Date of Patent: November 10, 2009
    Assignee: Merck Patent GmbH
    Inventors: Francis J. Carr, Graham Carter, Tim Jones, John Watkins, Matthew Baker
  • Publication number: 20090233806
    Abstract: Novel methods for the identification and/or sequencing of proteins are provided. These methods are particularly suited to screening antibody libraries and in preferred embodiments make use of mass spectrometry techniques for direct or indirect sequencing.
    Type: Application
    Filed: February 19, 2008
    Publication date: September 17, 2009
    Inventor: Francis J. Carr
  • Publication number: 20090221024
    Abstract: The present invention relates to novel T cell assay methods, in particular where T cell responses to test antigens are increased by removal of regulatory T cells. Novel assays where the timing of incubation with antigens or other samples is varied in order to optimize detection of T cell responses are described. The invention has particular application for measurement of human T cell responses to pharmaceuticals, allergens, irritants or other substances.
    Type: Application
    Filed: March 2, 2007
    Publication date: September 3, 2009
    Applicant: ANTITOPE LIMITED
    Inventors: Matthew Baker, Francis J. Carr, Alyson Rust, Laura Davies